Abingdon Health PLC Abingdon Analytical Laboratory opens at Doncaster

RNS Number : 3781Q

Abingdon Health PLC

17 December 2024

 

 

Abingdon Health plc

("Abingdon" or "the Company")

 

Abingdon Analytical Laboratory opens at Doncaster

 

York, U.K. 17 December 2024: Abingdon Health plc (AIM: ABDX), a leading international medical device contract development and manufacturing organisation (CDMO), announces the opening of its analytical laboratory at its Doncaster facilities. The laboratory will be operated by the Company's wholly-owned subsidiary, Abingdon Analytical Ltd.

 

The Group has been providing analytical laboratory services since 2023 as part of its strategy to offer a comprehensive CDMO service that supports its customers in bringing products to market. The services of an analytical laboratory make a significant contribution to a product's regulatory technical file, including product stability testing, specificity, sensitivity, assessment of detection limits, interference, cross-reactivity testing, and method comparisons. The technical file is a key requirement for regulatory approval by FDA, EU IVDR, UKCA and other regulatory authorities. Abingdon Analytical Ltd will provide its services for the lateral flow testing market and for adjacent sectors, such as other immunodiagnostic products and molecular diagnostics.

 

The Group is investing up to £1 million of the proceeds of the recent placing to strengthen its analytical laboratory service, part of which has financed this opening. 

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "This next step in our expansion provides a comprehensive analytical services laboratory, forming a bridge between our CDMO and regulatory service offerings, and linking our group companies, Abingdon Health, IVDeology and CS (Life Sciences). The capability to generate analytical and product performance data for use in a product's regulatory technical file adds another element to the broad portfolio of services we offer our customers. The first major contract announced today illustrates the benefit of adding this analytical capability to our CDMO offering."

 

Enquiries

 

Abingdon Health plc		www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer		Via Walbrook PR
Chris Hand, Executive Chairman
Zeus (Sole Broker and Nominated Adviser)		Tel: [phone]
Chris Fielding / Alexandra Campbell-Harris (Corporate Finance)
Fraser Marshall (Corporate Broking)
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]
Phillip Marriage	[phone]

 

 

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

 

About Abingdon Health plc

 

Abingdon Health Group is a leading Medtech contract service provider offering its services to an international customer base.

 

The Company's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCGPGRUPUPCUMM